+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vivus - logo

VIVUS is a biopharmaceutical company that develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company’s lead product Qsymia is a combination appetite suppressant/stimulant and seizure medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in overweight and obese adults. VIVUS was founded in 1991 and is headquartered in Campbell, California.

GABAA Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABAA Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Benzodiazepine Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Benzodiazepine Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Obesity: Competitive Landscape to 2026 - Product Thumbnail Image

Obesity: Competitive Landscape to 2026

  • Report
  • October 2018
  • 50 Pages
  • Global
From
Kainate Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Kainate Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
AMPA Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

AMPA Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
VIVUS LLC. - Company Profile and SWOT Analysis - Product Thumbnail Image

VIVUS LLC. - Company Profile and SWOT Analysis

  • SWOT Analysis
  • January 2025
  • 30 Pages
From
Loading Indicator